Pharsight Corporation, a leading provider of software and strategic services designed to optimize clinical drug development, today announced financial results for its second quarter of fiscal year 2006, ended September 30, 2005. For the second quarter, revenue was $5.9 million, an increase of 17% compared with revenue of $5.1 million in the second quarter of [...]
Archive for October, 2005
‘U.S. health officials have issued a warning about possible birth defects in infants born to women who take the antidepressant Paxil during the first trimester of pregnancy.
A study sponsored by GlaxoSmithKline, the drug’s maker, suggested that infants born to women taking Paxil were at about double the risk of birth defects compared with women taking [...]